CVD Prevention Optimal Value Pathway

Miles Freeman – NHS RightCare
Dr Matt Kearney – GP and National Clinical Director CVD Prevention

22nd November 2016
Structure

Rightcare
- Background
- Why OVP?
- Key elements of the pathway

CVD Prevention
- Approach
- Impact on outcomes
- Variation

OVP examples
- Walk through examples from the pathway
Rightcare

- Focus on data to compare spend, inputs and outcomes
- Belief that value can be maximised by eradicating unwarranted variation
- Publishes data packs for all CCGs and focus packs on disease areas
- Backed by delivery partners working with every CCG to embed approach
What issues are we looking to address with OVP’s?

- Time lag between adoption of best practice
- Service redesign necessarily slow and does not always capture the benefits intended
- Best practice models being developed in different geographical and clinical areas
- Lack of delivery mechanism for best practice to CCGs
- Wide variation in performance between areas – not accounted for by demography
Optimal Value Pathways – key components

• A compelling case for change that demonstrates the potential for improvement in clinical outcomes / value
• A best practice pathway – which has been developed with and signed off by all major stakeholders
• High value interventions – which parts of the pathway are susceptible to rapid improvement – biggest bang for buck
• Metrics that enable a CCG to understand its current performance, compared with peers and best practice – and help to quantify improvement to develop the business case for change
• Compendium of best practice case studies demonstrating what to change, how to change and a scale of improvement
• A delivery mechanism to ensure that pathways are publicised and considered by CCGs
CVD – getting serious about prevention

Why
• Relentless rise in preventable illness risks making the NHS unsustainable
• One in four premature deaths is caused by CVD especially heart attacks and strokes.

How
• Population level interventions are key ... but the NHS has critical role to play
  1. Advocate/champion for population level interventions
  2. Support for individual behaviour change
  3. Early diagnosis and optimal treatment of the high risk conditions
     Eg  Hypertension – 40% undiagnosed, 40% under treated
     Atrial Fibrillation – 2/3 at high risk not anticoagulated
     Cholesterol – half those at highest risk not on statins

Late diagnosis and under-treatment of these high risk conditions is common
This is low hanging fruit for CVD prevention
Secondary Prevention
The high risk conditions for CVD

- Heart attack
- Stroke
- PVD
- CKD
- Dementia
- BP
- AF
- Cholesterol
- Diabetes
- ‘Pre-diabetes’
High risk conditions – the evidence of risk

- High Blood Pressure
  - Contributes to half of all strokes and heart attacks

- Atrial Fibrillation
  - 5-fold increase in stroke risk and more likely to kill & disable

- High Cholesterol
  - Progressive increase in risk of heart attacks and strokes
High risk conditions – the evidence of treatment benefit

High Blood Pressure
Contributes to half of all strokes and heart attacks
Every 10mmHg BP reduction reduces risk of CV event by 20%

Atrial Fibrillation
5-fold increase in stroke risk and more likely to kill & disable
Anticoagulation reduces strokes by 2/3 in high risk AF

High Cholesterol
Progressive increase in risk of heart attacks and strokes
Every 1 unit reduction lowers risk of CV event by 25% each year
<table>
<thead>
<tr>
<th>Condition</th>
<th>Diagnosed</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>High Blood Pressure</td>
<td>Controlled to 140/90</td>
<td>6</td>
</tr>
<tr>
<td>Atrial Fibrillation</td>
<td>Known AF and on anticoagulant at time of stroke</td>
<td>1</td>
</tr>
<tr>
<td>High Cholesterol</td>
<td>10 year CVD risk above 20% and on statins</td>
<td>1</td>
</tr>
</tbody>
</table>
National variation shows high level of inequality and potential for quality improvement

Eg: Percentage of people known to have AF prescribed anticoagulation before their stroke

CCG comparison

Across England only one third of people with known AF who then suffer a stroke have been anticoagulated – despite the dramatic impact of this treatment on outcomes.

But wide variation between CCGs – from 20% to over 70%
1. Improving secondary prevention in BP, AF and cholesterol would significantly improve outcomes.

2. For example, NICE has modelled that if all appropriate patients with AF received anticoagulants, there would be **10,000 fewer strokes in England every year**.

3. If we only improved treatment in half the eligible patients, that would still prevent 5,000 strokes per year – **that’s 25 strokes in every CCG**.
Early detection and intervention in the high risk CVD conditions will prevent strokes and heart attacks

1. Hypertension, atrial fibrillation, high cholesterol, diabetes, non-diabetic hyperglycaemia and chronic kidney disease are high risk cardiovascular conditions
2. Most of the diagnosis and management of these conditions takes place in primary care
3. Late diagnosis and under treatment of these high risk conditions is common, and this substantially increases the incidence of stroke and heart attack
4. Systematic quality improvement is likely to have a cumulative impact in reducing incidence of stroke and heart attack
Developing the pathway

• Clinical consensus
• National working groups – utilised outputs
• Support and buy in from current and previous National Clinical Directors for Stroke, Heart Disease and Chronic Kidney Disease
• Co-developed with major voluntary sector groups (British Heart Foundation / Diabetes UK / AF Association / Stroke Association etc)
• Public Health England and NICE input
• Insight from Delivery Partners re usability with CCGs
# Cardiovascular Disease Prevention: Risk Detection and Management in Primary Care

## Cross Cutting
1. NHS Health Check - systematic detection of high BP, AF, NDH, T2DM, CKD, high cholesterol, CVD risk
2. System level action to support guideline implementation by clinicians
3. Support for patient activation, individual behaviour change and self management

## The Interventions

<table>
<thead>
<tr>
<th>Condition</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>High BP</td>
<td>Treatment</td>
</tr>
<tr>
<td>AF detection</td>
<td>&amp; anticoagulation</td>
</tr>
<tr>
<td>Detection, CVD risk assessment</td>
<td>Treatment</td>
</tr>
<tr>
<td>Type 2 Diabetes</td>
<td>Preventive intervention</td>
</tr>
<tr>
<td>Diabetes detection and</td>
<td>treatment</td>
</tr>
<tr>
<td>CKD detection and management</td>
<td></td>
</tr>
</tbody>
</table>

## The Opportunities

<table>
<thead>
<tr>
<th>Condition</th>
<th>Opportunities</th>
</tr>
</thead>
<tbody>
<tr>
<td>High BP</td>
<td>5 million un-diagnosed, 40% poorly controlled</td>
</tr>
<tr>
<td>AF</td>
<td>30% undiagnosed. Over half untreated or poorly controlled</td>
</tr>
<tr>
<td>Detection, CVD risk assessment</td>
<td>85% of FH undiagnosed. Most people at high CVD risk don't receive statins</td>
</tr>
<tr>
<td>Type 2 Diabetes</td>
<td>5 million with NDH. Most do not receive intervention</td>
</tr>
<tr>
<td>Diabetes detection and</td>
<td>940k undiagnosed. Many have poor BP &amp; proteinuria control</td>
</tr>
<tr>
<td>CKD detection and management</td>
<td>1.2m undiagnosed.</td>
</tr>
</tbody>
</table>

## The Evidence

<table>
<thead>
<tr>
<th>Condition</th>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>High BP</td>
<td>BP lowering prevents strokes and heart attacks</td>
</tr>
<tr>
<td>AF</td>
<td>Anticoagulation prevents 2/3 of strokes in AF</td>
</tr>
<tr>
<td>Detection, CVD risk assessment</td>
<td>Behaviour change and statins reduce lifetime risk of CVD</td>
</tr>
<tr>
<td>Type 2 Diabetes</td>
<td>Intensive behaviour change (eg NHS DPP) reduces T2DM risk 30-60%</td>
</tr>
<tr>
<td>Diabetes detection and</td>
<td>Control of BP, HbA1c and lipids improves CVD outcomes</td>
</tr>
<tr>
<td>CKD detection and management</td>
<td>Control of BP, CVD risk and proteinuria improves outcomes</td>
</tr>
</tbody>
</table>

## The Risk Condition

<table>
<thead>
<tr>
<th>Condition</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood Pressure</td>
<td></td>
</tr>
<tr>
<td>Atrial Fibrillation</td>
<td></td>
</tr>
<tr>
<td>High CVD risk &amp; Familial H/</td>
<td></td>
</tr>
<tr>
<td>cholesterol</td>
<td></td>
</tr>
<tr>
<td>Non Diabetic Hyperglycemia</td>
<td></td>
</tr>
<tr>
<td>'pre-diabetes'</td>
<td></td>
</tr>
<tr>
<td>Type 1 and 2 Diabetes</td>
<td></td>
</tr>
<tr>
<td>Chronic Kidney Disease</td>
<td></td>
</tr>
</tbody>
</table>

## Detection and 2°/3° Prevention

- 50% of all strokes & heart attacks, plus CKD & dementia
- 5-fold increase in strokes, often of greater severity
- Marked increase in premature death and disability from CVD
- Marked increase in Type 2 DM and CVD at an earlier age
- Marked increase in heart attack, stroke, kidney, eye, nerve damage
- Increase in CVD, acute kidney injury & renal replacement

## The Outcomes

<table>
<thead>
<tr>
<th>Condition</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood Pressure</td>
<td></td>
</tr>
<tr>
<td>Atrial Fibrillation</td>
<td></td>
</tr>
<tr>
<td>High CVD risk &amp; Familial H/</td>
<td></td>
</tr>
<tr>
<td>cholesterol</td>
<td></td>
</tr>
<tr>
<td>Non Diabetic Hyperglycemia</td>
<td></td>
</tr>
<tr>
<td>'pre-diabetes'</td>
<td></td>
</tr>
<tr>
<td>Type 1 and 2 Diabetes</td>
<td></td>
</tr>
<tr>
<td>Chronic Kidney Disease</td>
<td></td>
</tr>
</tbody>
</table>
1. **Systematic audit** to identify undiagnosed and under-treated patients – using the GRASP suite of tools, national audits and other local data solutions.

2. **Maximise NHS Health Check uptake and follow up** as systematic approach to detecting undiagnosed high risk CVD conditions.

3. **Commission new models** of diagnosis and management eg
   - Pharmacist
     - Diagnosis of AF and high BP
     - Monitoring and titration – BP and anticoagulant control
     - Adherence support – BP, statins, anticoagulants
   - New technologies – eg AliveCor, WatchBP Home, Health Stations
   - Self monitoring and self titration – BP and anticoagulant control

4. **Build local primary care leadership** to challenge unwarranted variation and drive quality improvement in high risk conditions
Works with Commissioning for Value focus packs
Links to CVIN practice level data

Reported vs Expected Prevalence AF

AF Diagnosis / No anticoagulation

---

18
Cardiovascular Disease Prevention – Risk Detection and Management in Primary Care

Cross Cutting:
1. NHS Health Check systematic detection of high BP, AF, NDH, T2DM, CKD, high cholesterol, CVD risk
2. System level action to support guideline implementation by clinicians
3. Support for patient activation, individual behaviour change and self management

The interventions
- High BP detection and treatment
- AF detection and anticoagulation
- Detection, CVD risk assessment, treatment
- Type 2 Diabetes preventive intervention
- Diabetes detection and treatment
- CKD detection and management

The Opportunities
- 5 million undiagnosed, 40% poorly controlled
- 30% undiagnosed. Over half untreated or poorly controlled
- 85% of FH undiagnosed & most people at high CVD risk do not receive statins
- 5 million undiagnosed. Most do not receive intervention
- 400k undiagnosed. 40% do not receive all 8 care processes
- 1.2m undiagnosed. Many have poor BP & proteinuria control

The Evidence
- BP lowering prevents strokes and heart attacks
- Anticoagulation prevents 2/3 of strokes in AF
- Behaviour change and statins reduce life time risk of CVD
- Intensive behaviour change (eg NHS DPP) reduces T2DM risk 30-60%
- Control of BP, HbA1c and lipids improves CVD outcomes
- Control of BP, CVD risk and proteinuria improves outcomes

The Risk condition
- Blood Pressure
- Atrial Fibrillation
- High CVD risk & Familial H/cholesterol
- NDH (‘pre-diabetes’)
- Type 1 and 2 Diabetes
- Chronic Kidney Disease

Detection and 2/3 Prevention
- 50% of all strokes & heart attacks, plus CKD & dementia
- 5-fold increase in strokes, often of greater severity
- Marked increase in premature death and disability from CVD
- Marked increase in Type 2 DM and CVD at an earlier age
- Marked increase heart attack, stroke, kidney, eye, nerve damage
- Increase in CVD, acute kidney injury & renal replacement

Outcomes
Links to overarching national strategies

Public Health England

Protecting and improving the nation’s health

Tackling high blood pressure
From evidence into action

Developed together by the 12 member organisations of the Blood Pressure System Leadership Board
Cardiovascular Disease Prevention – Risk Detection and Management in Primary Care

Cross Cutting: 1. NHS Health Check systematic detection of high BP, AF, NDH, T2DM, CKD, high cholesterol, CVD risk
2. System level action to support guideline implementation by clinicians
3. Support for patient activation, individual behaviour change and self management

The interventions
- High BP detection and treatment
- AF detection and anticoagulation
- Detection, CVD risk assessment, treatment
- Type 2 Diabetes preventive intervention
- Diabetes detection and treatment
- CKD detection and management

The Opportunities
- 5 million undiagnosed. 40% poorly controlled
- 30% undiagnosed. Over half untreated or poorly controlled
- 85% of FH undiagnosed & most people at high CVD risk do not receive statins
- 5 million undiagnosed. Most do not receive intervention
- 400k undiagnosed. 40% do not receive all 8 care processes
- 1.2m undiagnosed. Many have poor BP & proteinuria control

The Evidence
- BP lowering prevents strokes and heart attacks
- Anticoagulation prevents 2/3 of strokes in AF
- Behaviour change and statins reduce life time risk of CVD
- Intensive behaviour change (eg NHS DPP) reduces T2DM risk 30-60%
- Control of BP, HbA1c and lipids improves CVD outcomes
- Control of BP, CVD risk and proteinuria improves outcomes

The Risk condition
- Blood Pressure
- Atrial Fibrillation
- High CVD risk & Familial H/cholesterol
- NDH (‘pre-diabetes’)
- Type 1 and 2 Diabetes
- Chronic Kidney Disease

Detection and 2°/3° Prevention
- 50% of all strokes & heart attacks, plus CKD & dementia
- 5-fold increase in strokes, often of greater severity
- Marked increase in premature death and disability from CVD
- Marked increase in Type 2 DM and CVD at an earlier age
- Marked increase heart attack, stroke, kidney, eye, nerve damage
- Increase in CVD, acute kidney injury & renal replacement
Improvement opportunity

Blood pressure control in people with cardiovascular disease

NHS Greenwich CCG

Improvements can be made by managing hypertension in adults diagnosed with diabetes or stroke. This assumes that patients control their blood pressure consistently in order to reduce adverse disease events over a period of time.

The number of ‘events avoided’ is calculated by comparison to one of the best performing practices in this CCG.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Hypertensive adults with diabetes</th>
<th>Hypertensive adults with stroke</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current estimated number of patients treated with intervention</td>
<td>6,220</td>
<td>1,780</td>
</tr>
<tr>
<td>Additional patients CCG needs to treat to meet comparator intervention levels</td>
<td>644</td>
<td>81</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Condition</th>
<th>Disease event and NNT</th>
<th>Events avoided (opportunity)</th>
<th>Opportunities avoided over (NNT time frame)</th>
<th>One-year savings from events avoided - NHS</th>
<th>One-year savings from events avoided - social care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td>Stroke: 1 in 59</td>
<td>10</td>
<td>9 years</td>
<td>£109,445</td>
<td>£39,652</td>
</tr>
<tr>
<td></td>
<td>Heart attack: 1 in 204</td>
<td>3</td>
<td>9 years</td>
<td>£26,181</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Chronic kidney disease: 1 in 51</td>
<td>12</td>
<td>4 years</td>
<td>£3,018</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Heart failure: 1 in 42</td>
<td>15</td>
<td>4 years</td>
<td>£20,677</td>
<td>-</td>
</tr>
<tr>
<td>Previous stroke</td>
<td>Recurrent stroke: 1 in 27</td>
<td>3</td>
<td>4 years</td>
<td>£109,445</td>
<td>-</td>
</tr>
</tbody>
</table>
Links to high value interventions

CVD prevention - high value intervention in...

High blood pressure

1. Undertake systematic audit across practices
   - Identify people with possible undiagnosed hypertension
   - Identify people who are not treated to target
2. Work with practices and local authorities to maximise NHS Health Check uptake and follow up
3. Build local primary care leadership to challenge unwarranted variation and drive quality improvement in detection and management
4. Use practice based pharmacists to optimise management of hypertension
5. Commission ambulatory blood pressure monitoring service for diagnosis
6. Consider commissioning:
   - Systematic support for adherence from community pharmacists through MURs
   - BP self-test units eg surgery waiting rooms, community pharmacies, leisure centres
   - Digital solutions for self-monitoring and treatment optimisation

NICE Pathway

Return to pathway
Links to NICE Pathway - Hypertension overview

Adult having blood pressure measured

- Measuring blood pressure
- Diagnosis
  - Hypertension not diagnosed
    - Review at least 5-yearly
  - Hypertension diagnosed
    - Assessing cardiovascular risk and target organ damage
      - Management of hypertension
        - Review annually
- NICE pathway on hypertension in pregnancy
- NICE pathway on patient experience in adult NHS services
CVD prevention - high value intervention in...

High blood pressure

1. Undertake systematic audit across practices
   • Identify people with possible undiagnosed hypertension
   • Identify people who are not treated to target
2. Work with practices and local authorities to maximise NHS Health Check uptake and follow up
3. Build local primary care leadership to challenge unwarranted variation and drive quality improvement in detection and management
4. Use practice based pharmacists to optimise management of hypertension
5. Commission ambulatory blood pressure monitoring service for diagnosis
6. Consider commissioning:
   • Systematic support for adherence from community pharmacists through MURs
   • BP self-test units eg surgery waiting rooms, community pharmacies, leisure centres
   • Digital solutions for self-monitoring and treatment optimisation
Systematic audit across practices - Blackpool

A project to identify and treat people with existing but undiagnosed hypertension.

Project included:

- working with local general practice to identify people with a high blood pressure recording who have not received follow up intervention
- following up those people known by general practice to have hypertension who are not accessing medication or effectively managed
- holding community blood pressure awareness and testing events
- running an awareness-raising publicity and media campaign

The project resulted in 2,679 patients being added to GP hypertension registers (which will potentially prevent around 70 cardiovascular events per year). The size of GP hypertension registers rose by an average of 9.95%.

2,000 more people aged 45 years and over had a recent blood pressure reading entered onto their records, and there was an increase of 5% in the prescribing of anti-hypertensive drugs.
CVD prevention - high value intervention in...

Chronic Kidney Disease

1. Undertake systematic audit across practices to improve detection and management of CKD, and use audit data to focus quality improvement initiatives.

2. Consider commissioning CKD graphical surveillance to detect progression of CKD.

3. Work with practices and local authorities to maximise NHS Health Check uptake and follow up.

4. Build local primary care leadership to challenge unwarranted variation and drive quality improvement in detection and management.

5. Support people to self-manage their condition and make decisions about their own health to improve their quality of life.

6. Use practice based pharmacists to optimise management and risk reduction.
Identifying and monitoring people at greater risk of progressive chronic kidney disease (CKD).

We are leading a UK-wide project, supported by the Health Foundation, which involves around 20 renal units, pathology laboratories, their surrounding GP practices and clinical commissioning groups. The project is known as ASSIST-CKD. Our aim is to provide better and safer patient care by identifying people with CKD who are most at risk of disease progression. We want to ensure they are referred to secondary care at the right time, for the right treatment in the right care setting, to potentially reduce the rate of decline and so delay or avoid the need for dialysis or a kidney transplant.

Nearly 2 million people in the UK have been diagnosed with moderate-severe CKD by their GP but it is estimated that a further one million people remain undiagnosed as people with CKD often have little or no symptoms until the later stages of the disease. Patients also have an increased risk of cardiovascular disease and acute kidney injury (AKI).

We have based the project on a successful system that has been running at the Heart of England Foundation Trust (HEFT) in Birmingham for the past 10 years. It uses software to map data from routine blood tests (eGFR), creating graphs of kidney function over time. For patients with deteriorating kidney function, the participating laboratories send a report, including the graph, to the GP with a prompt that specialist advice may be needed. Another benefit is that patients with more stable CKD can be discharged back into primary care confident that their kidney function will continue to be monitored via these graphs.
CVD prevention - high value intervention in...

High Cholesterol/CVD risk

1. Maintain & Improve systematic collection and audit of data on cholesterol levels, high CVD risk and possible FH in practices to support detection and management

2. Achieve local clinical consensus and establish an integrated pathway for detection and management of raised cholesterol and CVD risk, which includes FH
   1. Identify & investigate possible undiagnosed hypercholesterolaemia and/or FH
   2. Identify and address suboptimal lipid management

3. Commission local service for FH investigation and cascade testing

4. Work with practices and local authorities to maximise NHS Health Check uptake

5. Build local primary care leadership to address unwarranted variation and drive quality improvement in detection and management

6. Strengthen risk assessment, detection and management through greater use of practice based and community pharmacies and consider commissioning systematic support specifically for statin adherence from community pharmacists through Medicine Use Reviews (MURs)
Do health checks improve risk factor detection in primary care? Matched cohort study using electronic health records

Alice S. Forster¹, Caroline Burgess¹, Hiten Dodhia², Frances Fuller³, Jane Miller³, Lisa McDermott¹, Martin C. Gulliford¹

¹Department of Primary Care and Public Health Sciences, King's College London, London, UK
²Public Health Directorate, London Boroughs of Lambeth and Southwark, London, UK
³Department of Public Health, London Borough of Lewisham, London, UK
Address correspondence to Martin Gulliford, E-mail: martin.gulliford@kcl.ac.uk

ABSTRACT

Background To evaluate the effect of NHS Health Checks on cardiovascular risk factor detection and inequalities.

Methods Matched cohort study in the Clinical Practice Research Datalink, including participants who received a health check in England between 1 April 2010 and 31 March 2013, together with matched control participants, with linked deprivation scores.

Results There were 91,618 eligible participants who received a health check, of whom 75,123 (82%) were matched with 182,245 controls. After the health check, 90% of men and 92% of women had complete data for blood pressure, total cholesterol, smoking and body mass index; a net 51% increase ($P < 0.001$) over controls. After the check, gender and deprivation inequalities in recording of all risk factors were lower than for controls. Net increase in risk factor detection was greater for hypercholesterolaemia (men +33%; women +32%) than for obesity (men +8%; women +4%) and hypertension in men only (+5%) (all $P < 0.001$). Detection of smoking was 5% lower in health check participants than controls ($P < 0.001$). Over 4 years, statins were prescribed to 11% of health check participants and 7.6% controls (hazard ratio 1.58, 95% confidence interval 1.53–1.63, $P < 0.001$).

Conclusion NHS Health Checks are associated with increased detection of hypercholesterolaemia, and to a lesser extent obesity and hypertension, but smokers may be under-represented.

Keywords cardiovascular diseases, cardiovascular risk, deprivation, electronic health records, gender, health inequalities, primary care, screening
Links to guidance and appraisals

CVD prevention - high value intervention in...

Atrial Fibrillation

1. Undertake systematic audit across practices (GRASP-AF audit tool)
   • Identify people with possible undiagnosed AF
   • Identify people with AF at high risk of stroke who are not anticoagulated or not maintained in the therapeutic range.

2. Work with practices and local authorities to maximise NHS Health Check uptake and follow up.
3. Build local primary care leadership to challenge unwarranted variation and drive quality improvement in detection and management.
4. Add pulse checking to existing GP and pharmacy enhanced services for people over 65.
5. Agree local clinical consensus and pathway for anticoagulation including the place of NOACs.
6. Consider commissioning:
   • Technologies such as WatchBP Home A and AliveCor to support AF detection in routine care
   • New models of anticoagulation control eg self-monitoring and community pharmacy monitoring
   • Systematic support for adherence from community pharmacists

NICE Pathway

Return to pathway
NICE recommends blood pressure device that can help prevent stroke

A new device that allows GPs and practice nurses to detect pulse irregularities and pick up cases of atrial fibrillation whilst measuring blood pressure has been recommended by NICE.

Atrial fibrillation (AF) causes the heart to beat with an irregular rhythm. It can be difficult to detect and subsequently diagnose as it is often asymptomatic and can be intermittent.

People with AF are at increased risk of developing blood clots and subsequent stroke, with 423,000 people aged 65 and over expected to have AF, of whom some will be living with the condition yet are undiagnosed.

In its medical technology guidance on WatchBP Home A, NICE says the device reliably detects AF and may increase the rate of detection when used in primary care. This will consequently allow for preventative treatment to be given and to reduce the incidence of AF-related stroke.

NICE also says the WatchBP Home A device should be considered for use in people with hypertension or those being screened for hypertension in primary care. People with suspected AF should have an electrocardiogram (ECG) in line with current AF guidance from NICE.

NICE estimates that around 74,000 people with AF will be detected nationally, who can then receive treatment if the device is used.

Cost savings are expected to reach £26.7 million per year, once a steady state of use is reached. Savings will mainly be achieved through avoiding stroke and through a reduction in the number of ECGs needed to check false-positive results, which occur when the pulse is taken by hand.
Links to audit tools

CVD prevention - high value intervention in...

Diabetes

1. Ensure 100% practice participation in National Diabetes Audit, and use audit data to focus quality improvement initiatives to improve achievement of the 8 key processes and 3 treatment targets.
2. Work with practices and local authorities to maximise NHS Health Check uptake and follow up.
3. Build local primary care leadership to challenge unwarranted variation and drive quality improvement in detection and management.
4. Ensure all patients with diabetes have access to routine care by a trained diabetes nurse.
5. Work with practices and education providers to maximise referral, uptake and retention in patient education programmes.
6. Consider commissioning systematic support for adherence from community pharmacists through medicines use reviews.

Return to pathway

NICE Pathway

Audit

Case Study

Case Study

Case Study

Case Study
National Diabetes Audit

The National Diabetes Audit (NDA) is the one of the largest annual clinical audits in the world, integrating data from both primary and secondary care sources, making it the most comprehensive audit of its kind.

To find out more about the NDA Programme check out this short presentation.

2015 - 2016 Audit Collection

The National Diabetes Audit 2015-16 is NOW CLOSED. The last date for data submission was Friday 19 August 2016. The audit team would like to thank you for your continued support of this audit and all your hard work.

You can still register your contact details with the NDA team and we will keep you up to date with the latest information about the audit and how to participate. Please include the following in your email: name, email address, practice name, practice code, clinical system.
The answers aren’t just with GP’s

CVD prevention - high value intervention in...

High blood pressure

1. Undertake systematic audit across practices
   • Identify people with possible undiagnosed hypertension
   • Identify people who are not treated to target
2. Work with practices and local authorities to maximise NHS Health Check uptake and follow up
3. Build local primary care leadership to challenge unwarranted variation and drive quality improvement in detection and management
4. Use practice based pharmacists to optimise management of hypertension
5. Commission ambulatory blood pressure monitoring service for diagnosis
6. Consider commissioning:
   • Systematic support for adherence from community pharmacists through MURs
   • BP self-test units eg surgery waiting rooms, community pharmacies, leisure centres
   • Digital solutions for self-monitoring and treatment optimisation

NICE Pathway

Return to pathway
Build local primary care leadership to challenge unwarranted variation and drive quality improvement in detection and management.

**Using practice based pharmacists to manage hypertension in Dudley**

**KEY LEARNING**

- GPs were engaged through a practice engagement scheme and the hypertension action plans.
- A three year CCG Local Quality Premium for hypertension provided a funding incentive.
- Hypertension was made a clinical priority for CCG.

**INTRODUCTION**

- In 2002, statistics for Dudley PCT showed that the standardised mortality rate from hypertensive disease was double the England average.
- Further local audit in 2013 identified there were 11,000 patients diagnosed with hypertension whose blood pressure was not managed to 150/90mmHg, and an estimated 27,800 patients missing from hypertension registers.

Dudley CCG has the highest recorded prevalence of hypertension in England at 17.7%, or 54,606 people, compared with an average of 13.7%(QOF 2013/14).

**WHY WAS A PROJECT TO TARGET HIGH BLOOD PRESSURE DEVELOPED?**

A pharmacist-led audit in Dudley identified several underlying issues:
- Difficulty identifying patients with hypertension
- Practices only treating patients to the QOF target, not the evidence-base
- High levels of exception reporting
- Patients both being not recalled and not attending follow-up appointments after diagnosis
- Patients perceiving hypertension as not important, probably because this is silent and not a visible condition.
Or always with health professionals

CVD prevention - high value intervention in...

High blood pressure

1. Undertake systematic audit across practices
   • Identify people with possible undiagnosed hypertension
   • Identify people who are not treated to target
2. Work with practices and local authorities to maximise NHS Health Check uptake and follow up
3. Build local primary care leadership to challenge unwarranted variation and drive quality improvement in detection and management
4. Use practice based pharmacists to optimise management of hypertension
5. Commission ambulatory blood pressure monitoring service for diagnosis
6. Consider commissioning:
   • Systematic support for adherence from community pharmacists through MURs
   • BP self-test units eg surgery waiting rooms, community pharmacies, leisure centres
   • Digital solutions for self-monitoring and treatment optimisation

NICE Pathway

Return to pathway
Case study

Stoke-on-Trent: telehealth helps patients manage their own conditions

The Advice and Interactive text Messaging (AIM) for Health programme began across England in March 2013.

The programme included:

- lead clinician developing 4 protocols to support diagnosis or management of high blood pressure (hypertension) in different circumstances
- registering nearly 300 patients in 10 months to follow the protocols through their primary care team (GPs) and take part in the programme
- patients submitting their blood pressure (BP) readings regularly by text
- telehealth system, ‘Flo’, sending automated text messages back to patients with advice, instructions or other messages based on their readings
- clinicians checking their submitted readings (at least weekly review on Florence website) and contacting patients if necessary with further instructions
Summary slide

• First in a series of pathways designed to speed adoption of best practice and reduce variation
• CVD Prevention can be greatly increased through systematic, resourced quality improvement within primary care
• Great benefits in terms of patient outcomes and cost avoidance
• Pathway has all the tools required for commissioners to understand the benefits and implement change
• Has been endorsed by all major stakeholders
• Launched September 29th 2016 – World Heart Health Day
• Available here: https://www.england.nhs.uk/rightcare/intel/cfv/cvd-pathway